Literature DB >> 15719379

Surgical treatment of non-functioning pancreatic islet cell tumors.

Maria A Kouvaraki1, Carmen C Solorzano, Suzanne E Shapiro, James C Yao, Nancy D Perrier, Jeffrey E Lee, Douglas B Evans.   

Abstract

Pancreatic endocrine tumors (PETs) are rare neoplasms originating from the amine precursor uptake and decarboxylation (APUD) stem cells. Although the majority of PETs are sporadic, they frequently occur in familial syndromes. PETs may cause a variety of functional syndromes or symptoms of local progression if they are non-functional. General neuroendocrine tumor markers are highly sensitive in the diagnostic assessment of a PET. Imaging studies for tumor localization and staging include computer tomography (CT) scan, magnetic resonance imaging (MRI), In(111)-octreotide scan, MIBG, and endoscopic ultrasonography (EUS). Treatment of PETs often requires a multi-modality approach; however, surgical resection remains the only curative therapy for localized (non-metastatic) disease. Treatment of metastatic disease includes biologic agents, cytotoxic chemotherapy, and liver-directed therapies. (c) 2005 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15719379     DOI: 10.1002/jso.20178

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  17 in total

Review 1.  Clinical pathways for pancreatic neuroendocrine tumors.

Authors:  Angela Alistar; Max Sung; Michelle Kim; Randall F Holcombe
Journal:  J Gastrointest Cancer       Date:  2012-12

Review 2.  Surgical treatment of gastrointestinal neuroendocrine tumors.

Authors:  Volker Fendrich; Detlef K Bartsch
Journal:  Langenbecks Arch Surg       Date:  2011-02-01       Impact factor: 3.445

3.  Small cell and large cell neuroendocrine carcinomas of the pancreas are genetically similar and distinct from well-differentiated pancreatic neuroendocrine tumors.

Authors:  Shinichi Yachida; Efsevia Vakiani; Catherine M White; Yi Zhong; Tyler Saunders; Richard Morgan; Roeland F de Wilde; Anirban Maitra; Jessica Hicks; Angelo M Demarzo; Chanjuan Shi; Rajni Sharma; Daniel Laheru; Barish H Edil; Christopher L Wolfgang; Richard D Schulick; Ralph H Hruban; Laura H Tang; David S Klimstra; Christine A Iacobuzio-Donahue
Journal:  Am J Surg Pathol       Date:  2012-02       Impact factor: 6.394

4.  Breast and lung metastasis from pancreatic neuroendocrine carcinoma.

Authors:  Shevonne Satahoo-Dawes; Joshua Palmer; Eddie W Manning; Joe Levi
Journal:  World J Radiol       Date:  2011-01-28

5.  Implications of incidentally discovered, nonfunctioning pancreatic endocrine tumors: short-term and long-term patient outcomes.

Authors:  Alex B Haynes; Vikram Deshpande; Thun Ingkakul; Parsia A Vagefi; Jackie Szymonifka; Sarah P Thayer; Cristina R Ferrone; Jennifer A Wargo; Andrew L Warshaw; Carlos Fernández-del Castillo
Journal:  Arch Surg       Date:  2011-05

Review 6.  Pancreatic endocrine neoplasms: epidemiology and prognosis of pancreatic endocrine tumors.

Authors:  Thorvardur R Halfdanarson; Joseph Rubin; Michael B Farnell; Clive S Grant; Gloria M Petersen
Journal:  Endocr Relat Cancer       Date:  2008-06       Impact factor: 5.678

Review 7.  Surgical management of pancreatic endocrine tumors.

Authors:  Volker Fendrich; Jens Waldmann; Detlef K Bartsch; Peter Langer
Journal:  Nat Rev Clin Oncol       Date:  2009-06-09       Impact factor: 66.675

8.  Small pancreatic and periampullary neuroendocrine tumors: resect or enucleate?

Authors:  Susan C Pitt; Henry A Pitt; Marshall S Baker; Kathleen Christians; John G Touzios; James M Kiely; Sharon M Weber; Stuart D Wilson; Thomas J Howard; Mark S Talamonti; Layton F Rikkers
Journal:  J Gastrointest Surg       Date:  2009-06-23       Impact factor: 3.452

9.  Metastatic pancreatic neuroendocrine tumor presenting as a pituitary space occupying lesion: a case report.

Authors:  Chamutal Gur; Gadi Lalazar; Asher Salmon; Victoria Dubiner; David J Gross
Journal:  Pituitary       Date:  2008       Impact factor: 4.107

10.  Is laparoscopic resection adequate in patients with neuroendocrine pancreatic tumors?

Authors:  Laureano Fernández-Cruz; Laia Blanco; Rebeca Cosa; Héctor Rendón
Journal:  World J Surg       Date:  2008-05       Impact factor: 3.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.